426 related articles for article (PubMed ID: 23057549)
21. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
[TBL] [Abstract][Full Text] [Related]
22. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.
Lai ZS; Yeh TK; Chou YC; Hsu T; Lu CT; Kung FC; Hsieh MY; Lin CH; Chen CT; James Shen CK; Jiaang WT
Eur J Med Chem; 2021 Jan; 209():112938. PubMed ID: 33109398
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
Pearson HA
Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181
[No Abstract] [Full Text] [Related]
24. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Green NS; Barral S
Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
[TBL] [Abstract][Full Text] [Related]
25. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
Ajanta H; Chakraborty S; Madhusnata D; Bhattacharya DK; Manisha D
J Assoc Physicians India; 2002 Aug; 50():1034-5. PubMed ID: 12421025
[TBL] [Abstract][Full Text] [Related]
26. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
27. Genetic variation of Krüppel-like factor 1 (KLF1) and fetal hemoglobin (HbF) levels in β
Khamphikham P; Sripichai O; Munkongdee T; Fucharoen S; Tongsima S; Smith DR
Int J Hematol; 2018 Mar; 107(3):297-310. PubMed ID: 29067594
[TBL] [Abstract][Full Text] [Related]
28. Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.
Gravia A; Chondrou V; Sgourou A; Papantoni I; Borg J; Katsila T; Papachatzopoulou A; Patrinos GP
Pharmacogenomics; 2014 Jul; 15(10):1355-64. PubMed ID: 25155936
[TBL] [Abstract][Full Text] [Related]
29. Use of hydroxyurea in children with sickle cell disease: what comes next?
Ohene-Frempong K; Smith-Whitley K
Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
[TBL] [Abstract][Full Text] [Related]
30. Hydroxyurea in thalassemia intermedia--a promising therapy.
Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.
Chou YC; Chen RL; Lai ZS; Song JS; Chao YS; Shen CK
Mol Cell Biol; 2015 Jul; 35(14):2541-53. PubMed ID: 25986606
[TBL] [Abstract][Full Text] [Related]
32. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
[TBL] [Abstract][Full Text] [Related]
33. Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients.
Papassotiriou I; Voskaridou E; Stamoulakatou A; Loukopoulos D
Hematol J; 2000; 1(5):295-300. PubMed ID: 11920206
[TBL] [Abstract][Full Text] [Related]
34. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
[TBL] [Abstract][Full Text] [Related]
35. Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia.
Fibach E; Burke LP; Schechter AN; Noguchi CT; Rodgers GP
Blood; 1993 Mar; 81(6):1630-5. PubMed ID: 7680923
[TBL] [Abstract][Full Text] [Related]
36. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
Musallam KM; Taher AT; Cappellini MD; Sankaran VG
Blood; 2013 Mar; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
[TBL] [Abstract][Full Text] [Related]
37. Hydroxyurea in children: present and future.
Vichinsky EP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
[TBL] [Abstract][Full Text] [Related]
38. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
Watanapokasin R; Sanmund D; Winichagoon P; Muta K; Fucharoen S
Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
[TBL] [Abstract][Full Text] [Related]
39. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
40. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
